Gene polymorphisms and chemotherapy in non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 12, Issue 8, 2009, Pages 837-840

  Osawa, Kayo ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Drug therapy; Genetic polymorphism; Lung neoplasms

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; CARBOXYLESTERASE; CISPLATIN; CYTOCHROME P450 3A4; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN; NAVELBINE; ORGANIC ANION TRANSPORTER 1; PACLITAXEL; TUMOR MARKER; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; XRCC3 PROTEIN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; DNA REPAIR; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; GLUCURONIDATION; HUMAN; INTRON; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTION; PROMOTER REGION; REVIEW; TREATMENT OUTCOME;

EID: 69949162040     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.08.01     Document Type: Review

References (36)

1. Osawa Y, Osawa K, Miyaishi A, et al. NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev, 2007, 8(1): 103-108.
2. Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science, 2001, 291(5507): 1284-1289.
3. Miyaishi A, Osawa K, Osawa Y, et al. MUTYH Gln324His gene polymorphism and genetic susceptibility for lung cancer in a Japanese population. J Exp Clin Cancer Res, 2009, 28: 10.
4. Koo SH, Lee EJ. Pharmacogenetics approach to therapeutics. Clin Exp Pharmacol Physiol, 2006, 33(5-6): 525-532.
5. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 2002, 346(2): 85-91. (Pubitemid 34438898)
6. Sai K, Saito Y, Fukushima-Uesaka H, et al. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol, 2008, 62(3): 529-537.
7. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res, 2001, 7(8): 2182-2194.
8. Ando Y, Ueoka H, Sugiyama T, et al. Polymorphisms of UDP- glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit, 2002, 24(1): 111-116. (Pubitemid 34106739)
9. Araki K, Fujita K, Ando Y, et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci, 2006, 97(11): 1255-1259. (Pubitemid 44430653)
10. Lampe JW, Bigler J, Horner NK, et al. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics, 1999, 9(3): 341-349. (Pubitemid 29376378)
11. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res, 2000, 60(24): 6921-6926. (Pubitemid 32059164)
12. Font A, Sánchez JM, Tarón M, et al Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs, 2003, 21(4): 435-443.
13. Jada SR, Lim R, Wong CI, et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci, 2007, 98(9): 1461-1467.
14. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol, 2006, 24(15): 2237-2244.
15. Fujita K, Ando Y, Nagashima F, et al. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol, 2007, 60(4): 515-522. (Pubitemid 47084262)
16. Han JY, Lim HS, Shin ES, et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer, 2008, 59(1): 69-75.
17. Takane H, Miyata M, Burioka N, et al. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit, 2007, 29(5): 666-668. (Pubitemid 47494070)
18. Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 2007, 110(1): 138-147.
19. Sancar A. DNA repair in humans. Annu Rev Genet, 1995, 29: 69-105.
20. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 2004, 44(3): 311-316. (Pubitemid 38609439)
21. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol, 2004, 15(8): 1194-1203. (Pubitemid 39199306)
22. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res, 2004, 10(15): 4939-4943. (Pubitemid 39099767)
23. de las Peñas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol, 2006, 17(4): 668-675.
24. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res, 2008, 14(6): 1797-1803.
25. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res, 2005, 11(4): 1534-1538. (Pubitemid 40315237)
26. Feng J, Sun X, Sun N, et al. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai), 2009, 41(5): 429-435.
27. Li Y, Gu S, Wu Q, et al. No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis. Eur J Hum Genet, 2007, 15(9): 967-973. (Pubitemid 47308473)
28. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol, 2004, 22(13): 2594-2601. (Pubitemid 41103746)
29. Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res, 2007, 13(10): 2876-2881. (Pubitemid 46849561)
30. Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cybdine deaminase polymorphism. J Clin Oncol, 2007, 25(1): 32-42. (Pubitemid 350003048)
31. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007, 7(3): 169-181. (Pubitemid 46316032)
32. Tiseo M, Capelletti M, De Palma G, et al. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol, 2008, 3(10): 1104-1111.
33. Huang CL, Yang CH, Yeh KH, et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer, 2009, 64(3): 346-351.
34. Liu W, Innocenti F, Wu MH, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res, 2005, 65(1): 46-53. (Pubitemid 40070794)
35. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J, 2008, 8(2): 129-138.
36. Nomura M, Shigematsu H, Li L, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med, 2007, 4(4): e125. (Pubitemid 46658773)